Indivior PLC Ordinary Shares

Indivior PLC Ordinary Shares Earnings Recaps

INDV Health Care 1 recap
Q3 2025 Oct 31, 2025

Indivior PLC reported strong Q3 2025 results with a 15% increase in SUBLOCADE sales, driving a 2% rise in total net revenue, and raised full year guidance on adjusted EBITDA growth.

Key takeaways
  • Adjusted EBITDA grew 14% year-over-year, reflecting improved operational efficiency.
  • Raised full year 2025 revenue guidance, projecting a 10% increase in SUBLOCADE net revenue.
  • Implemented $150 million in annual cost reductions through organizational simplification and strategic focus.
  • Continued stability observed in SUBOXONE Film pricing in the U.S.
  • Solid unit dispense growth of 8% for SUBLOCADE, underscoring effective commercial execution strategies.